Screens for genetic mutations have been instrumental in identifying genes needed to execute particular biological processes. They have also helped to resolve the function of individual genes. Now the notion of large-scale mutagenesis screens in mouse, an experimental model for humans, is becoming a reality.
At the heart of genetics lie screens for mutations that cause detectable and heritable changes in biological form or function. If altering a particular gene alters a biological process, then probably that gene's normal protein product operates in that process. Genetic screens thus provide a relatively unbiassed route for identifying the genes required for a given biological process. They may also indicate when in that process the product of a particular gene is needed, and how it interacts with or relates to other genes operating in the same process. In this way, a hierarchy of genetic requirements can be compiled, even before the molecular nature of the gene products is known. Can large scale mutagenesis screens be used to dissect mammalian biology?
The success of a genetic screen depends on several factors. Scale is important: the phenotypes of enough individuals need to be studied to ensure that mutations in as many genes as possible -ideally, all genes -are represented. Indeed, more than one mutation per gene is desirable, different mutations exposing different facets of function. In reality, however, some mutations will be lethal before the phenotype is examined, which means that the ideal of saturation is seldom realised. How sensitive the screen will be depends on how good the criteria are for distinguishing between normal and abnormal phenotype. Often it is easier to identify mutations in organisms that otherwise have identical genomes and minimal phenotypic variability between individuals.
The type of mutation being sought will also be important. Removing or attenuating gene function generally reveals more about normality than adding to or changing gene function. If a plant is deprived of water, it will die because normally it needs water. If it is given detergent it will also die, not because normally it needs detergent, but because the addition of soap changes water into a poison. So lossof-function mutations, which tend to be recessive in diploid organisms, are usually more informative than gainof-function mutations, which tend to be dominant. The ability to map mutations to their location in the genome -on which chromosome they reside and where -is essential, not only in helping to distinguish between different genes with similar effects, but also in cloning the mutated gene and determining the molecular function of its product.
The power of genetic screens in unravelling complex biological processes is illustrated by the understanding of cell proliferation that has been gained from the systematic analysis of yeast mutants [1] , and the counter-intuitive revelations about pattern formation which emerged from studying recessive mutations in fly embryos [2] . Are such screens suited to animals with larger genomes -in particular, mammals -in order to dissect their biological peculiarities? The recent mutant screens of zebrafish embryos bode well [3, 4] . Hundreds of recessive mutations affecting various developmental pathways have been recovered, many of which may prove relevant to other vertebrates. But no matter how plausible the inferences drawn from zebrafish, these cannot substitute for a direct analysis of mammalian biology.
Mice are the most accessible and prolific experimental mammals and, apart from humans, the mammal whose genetics are best understood. Despite this, mutations are recognised in only about 2% of the anticipated 60,000 mouse genes. It is time to expand this resource, taking advantage of the genetic homogeneity of existing inbred strains of mice. Germline mutations, which will be passed to subsequent generations, are usually induced in mice either by manipulating the DNA of embryos or by chemically modifying the DNA of sperm in the adult. Targetting mutations to specific genes by DNA manipulation is a powerful tool in mice, but too laborious a method for saturating the genome with mutations. Gene trap technology, where DNA is randomly inserted into the genome but only likely mutagenic insertions within gene sequences are recovered, may be more suitable for mutating all genes. But at present the most efficient mutagen in mice is the alkylating agent ethylnitrosourea (ENU), which produces predominantly point mutations in sperm. Tracing a mutant phenotype induced by ENU to the gene in which a single base-pair change has occurred requires formidable knowledge of the genome. The absolute benefit of genome-wide ENU mutagenesis screens therefore depends critically on the speed, accuracy and resolution with which a comprehensive physical map of the mouse genome is generated.
Large-scale mutagenesis screens in mice are now under way (reviewed in [5] ). There are phenotype-based screens looking for mutations that disrupt specific processes. These are particularly apposite where it is not possible to study the process in depth in the human population. Embryogenesis is an obvious example. Behavioural mutants might be another, although it is salutary to consider that behavioural genetics in flies has pointed more to an ignorance of how the central nervous system develops than how it operates [6] . There are also genome-based screens that are prompted by the pressing need to determine the function of all genes in the genome. The Human Genome Project will soon have determined the DNA sequences encoding the full repertoire of proteins needed to make a human being. Systematically mutating every gene in the mouse genome and documenting the consequences for the animal is one way of deciphering what these genes do.
Most genome-wide searches for mutations affecting mouse biology focus on identifying dominant mutations whose phenotypes can be detected in viable mice. The immediate offspring of males injected with ENU are subjected to a series of tests designed to expose defects in a variety of organ systems, ranging from motor function to hearing to blood composition (for example, see http:/www.mgu.har.mrc.ac.uk/mutabase/ or http://www.gsf.de/isg/groups/enu/mutants/index.html). It is too early to judge what the rewards will be from these screens. Cynics might argue that the human population already offers the best resource for identifying dominant traits. Moreover, dominant mutations in some genes will be incompatible with viability, and some phenotypes may stem from fortuitous combinations of several mutations. There is also the problem that, if dominance is due to changing the function of a gene product, this may not greatly illuminate what it normally does. Nonetheless, this approach has already borne important fruit: Clock, the first mutation known to disrupt circadian rhythm in a mammal, was identified from a dominant screen [7] .
Recessive screens have been carried out in mice by crossing mutagenised males, or their offspring, with animals that already carry a deletion in their genome [5] . In this way, only one copy of each gene within the deletion is present and inherited from the mutagenised mouse, so if one of these genes has been mutated, a recessive phenotype will be exposed. Although a collection of deletions exists amongst mouse stocks, this can now be expanded and tailored by physical or molecular chromosome engineering in embryonic stem cells [8, 9] . Although it is unlikely that a deletion series can be generated that covers the whole genome, welldesigned phenotype screens should permit the functions of many chromosomal regions to be pieced together.
What about phenotype-based genome-wide recessive screens? These are few and far between, the search for recessive mutations affecting phenylalanine metabolism being the most notable until recently [10] . This summer, Karsakis et al. [11] published a study aimed at assessing the feasibility of screening the mouse genome for recessive mutations that affect embryonic pattern at midgestation. As many adult anomalies stem from developmental defects, and many molecular pathways are first used during development, a screen for such embryonic phenotypes is a brave but judicious beginning.
Karsakis et al. [11] looked for phenotypes at a stage when most mutant embryos with patterning defects should still be alive and identifiable from inspection in a dissecting microscope (Figure 1 ). Out of 130 separate families, only 86 produced enough second generation females for screening embryonic progeny. Five mutant linesapproximately 6% of the total -were identified. One of these had a complex genetic basis, but the other four mutations each mapped to single loci and behaved as simple recessive traits. Two mutations affected closure of the neural tube -one of which proved to be allelic to an existing spontaneous mutation -while the other two caused earlier and more widespread defects.
The importance of this study is that it demonstrates the feasibility of a genome-wide search for recessive genes affecting development, and the relative ease with which mutations can be mapped (and, hopefully, soon cloned). If ENU produces one new mutation per gene for every 700 mutagenised families screened, then it is reasonable to suppose that screening a mere 1000 families will reveal most genes in which mutations give recognisable midgestation embryonic phenotypes. This is not such a daunting prospect, especially once the physical genome map is complete.
The attraction of phenotype-based screens is that they are not just about gene discovery, but rather about gene interaction and the genetic networks which dictate form and function. In this gene obsessed age, it is important to remember that the genetic harvest is not just a dictionary of gene sequences, but also a compendium of phenotypes. Biologists have to be committed to studying a new generation of mouse mutants and using these phenotypes to interpret the language of the genes.
